Widely read:
Adobe Stock
Pfizer just reminded the market it's not done making headlines. Its India arm reported an 85 per cent spike in profit and handed out a Rs 165 dividend. And while investors were still cheering that, the global parent dropped a $6 billion deal on the table, doubling down on cancer drug innovation.
Markets loved it. Pfizer India's stock shot up over 10 per cent today (May 20), hitting Rs 4,995.85 intraday.
Why the rally
Let's break it down:
-
Q4 FY25 net profit
: Rs 330.94 crore, up 85 per cent YoY
-
Revenue
: Rs 678.4 crore, up 9.5 per cent
-
Total FY25 dividend
: Rs 165 per share
-
Final: Rs 40
-
Special: Rs 30 (75-year milestone)
- Another Rs 95 from asset sale gains
That kind of generosity doesn't go unnoticed. Especially when it's backed by a solid quarter.
But the bigger story? Oncology
Pfizer Inc just inked a $6 billion licensing deal with China's 3SBio for a next-gen cancer drug, SSGJ-707.
What it means:
-
Pfizer gets global rights (minus China)
to develop and sell the drug
-
Pays $1.25 billion upfront
- Could pay up to $4.8 billion more if the drug delivers in trials and sales
The drug is still being tested for multiple cancers, but if it lands, this could be Pfizer's next blockbuster. And investors know that.
What Pfizer does
Pfizer Ltd is the Indian arm of the global pharma behemoth. It sells a range of prescription drugs in India—think heart meds, vaccines, anti-infectives, and painkillers. It's also the name behind the COVID vaccine juggernaut.
Snapshot
| Metric | Value |
|---|---|
| Market cap | Rs 20,423 cr |
| Net profit (TTM) | Rs 616 cr |
| Revenue (TTM) | Rs 2,236 cr |
| Dividend (FY25) | Rs 165/share |
| P/E ratio | ~33x |
| 1Y stock return | ~10 per cent |
Value Research Online ratings (Pfizer - India)
-
⭐
Overall
: 3/5
-
Quality
: 10/10
-
Growth
: 6/10
-
Valuation
: 4/10
- Momentum : 3/10
What investors should keep in mind
Pfizer's delivering where it counts—both in the lab and on the balance sheet. Yes, the stock's on a sugar high. That said, you've got:
-
Consistent profit growth
-
A strong dividend track record
- Global innovation pipeline from the parent company
Keep it on your radar.
Why smart investors trust expert research
Want sharper, stock-focused guidance? Value Research Stock Advisor gives you expert-researched stock recommendations, long-term strategies and the discipline to help you build real wealth. Join thousands of successful Indian investors who trust us to guide their equity journey.
Check it out here: Value Research Stock Advisor
Disclaimer: This is not a stock recommendation. This story was created with the assistance of artificial intelligence and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
